“Increasing Focus on Combination Therapies”
- One notable trend in the HER2+ gastric cancer market is the increasing focus on combination therapies. Researchers and healthcare providers are exploring the synergy between HER2-targeted therapies and other treatment modalities, such as chemotherapy, immune checkpoint inhibitors, and other novel biologics. This trend aims to improve patient outcomes by addressing tumor heterogeneity and overcoming resistance mechanisms that may limit the effectiveness of single-agent therapies
- For instance, In August 2020, HER2-targeted therapy trastuzumab deruxtecan (Enhertu), was approved for patients with HER2-positive metastatic gastric cancer. Clinical trials have shown that when combined with chemotherapy or other drugs, it significantly enhances progression-free survival
- The positive results from these studies have spurred more research into multi-drug combinations to maximize therapeutic efficacy and improve overall survival rates in patients with advanced HER2+ gastric cancer. This approach is expected to drive market growth in the coming years
